Table 2. Meta-analysis of the association between TERT rs2736098 polymorphism and overall cancer risk.
| Variables | No. of | Homozygous | Heterozygous | Recessive | Dominant | Allele | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| studies | AA vs. GG | AG vs. GG | AA vs. AG/GG | AA/AG vs. GG | A vs. G | ||||||||||
| OR (95% CI) | P het | OR (95% CI) | P het | OR (95% CI) | P het | OR (95% CI) | P het | OR (95% CI) | P het | ||||||
| All a | 33 | 1.26 (1.09–1.47) | < 0.001 | 1.09 (0.99–1.19) | < 0.001 | 1.22 (1.09–1.36) | < 0.001 | 1.13 (1.02–1.24) | < 0.001 | 1.11 (1.04–1.20) | < 0.001 | ||||
| Cancer type | |||||||||||||||
| Lung | 9 | 1.71 (1.51–1.94) | 0.453 | 1.18 (1.05–1.34) | 0.037 | 1.60 (1.42–1.80) | 0.783 | 1.29 (1.14–1.46) | 0.021 | 1.29 (1.18–1.41) | 0.033 | ||||
| Bladder | 5 | 1.62 (1.27–2.08) | 0.258 | 1.17 (0.93–1.45) | 0.068 | 1.52 (1.24–1.85) | 0.569 | 1.26 (1.01–1.57) | 0.045 | 1.25 (1.08–1.45) | 0.086 | ||||
| HCC | 4 | 1.16 (0.87–1.54) | 0.161 | 1.38 (0.97–1.95) | 0.001 | 1.01 (0.78–1.30) | 0.181 | 1.33 (0.98–1.79) | 0.004 | 1.15 (0.97–1.36) | 0.040 | ||||
| Breast | 3 | 0.64 (0.46–0.89) | 0.235 | 0.87 (0.68–1.13) | 0.194 | 0.71 (0.57–0.88) | 0.361 | 0.80 (0.59–1.07) | 0.117 | 0.82 (0.67–0.99) | 0.107 | ||||
| SCCHN | 2 | 0.90 (0.70–1.16) | 0.963 | 0.92 (0.81–1.05) | 0.577 | 0.93 (0.73–1.20) | 0.862 | 0.92 (0.81–1.04) | 0.627 | 0.94 (0.85–1.03) | 0.751 | ||||
| Colorectal | 2 | 0.48 (0.28–0.83) | 0.611 | 0.54 (0.21–1.40) | 0.047 | 0.73 (0.46–1.14) | 0.630 | 0.59 (0.31–1.12) | 0.097 | 0.72 (0.56–0.92) | 0.371 | ||||
| Others | 8 | 1.26 (0.92–1.73) | < 0.001 | 1.02 (0.80–1.30) | < 0.001 | 1.23 (1.06–1.42) | 0.121 | 1.06 (0.83–1.36) | < 0.001 | 1.08 (0.91–1.27) | < 0.001 | ||||
| Ethnicity | |||||||||||||||
| Asians | 23 | 1.43 (1.26–1.63) | < 0.001 | 1.15 (1.05–1.25) | < 0.001 | 1.33 (1.19–1.50) | 0.001 | 1.21 (1.11–1.32) | < 0.001 | 1.19 (1.12–1.27) | < 0.001 | ||||
| Caucasians | 10 | 0.88 (0.61–1.25) | < 0.001 | 0.90 (0.72–1.11) | < 0.001 | 0.97 (0.80–1.17) | 0.024 | 0.90 (0.72–1.11) | < 0.001 | 0.93 (0.80–1.08) | < 0.001 | ||||
| Source of control | |||||||||||||||
| HB | 24 | 1.38 (1.16–1.65) | < 0.001 | 1.16 (1.02–1.31) | < 0.001 | 1.29 (1.15–1.50) | 0.001 | 1.20 (1.06–1.37) | < 0.001 | 1.17 (1.07–1.28) | < 0.001 | ||||
| PB | 9 | 1.03 (0.82–1.29) | < 0.001 | 0.93 (0.87–0.99) | 0.549 | 1.05 (0.85–1.31) | < 0.001 | 0.96 (0.88–1.04) | 0.164 | 0.99 (0.90–1.09) | 0.002 | ||||
| Quality score | |||||||||||||||
| > 9 | 15 | 1.30 (1.10–1.54) | < 0.001 | 1.02 (0.96–1.08) | 0.530 | 1.29 (1.11–1.49) | 0.001 | 1.07 (0.99–1.16) | 0.021 | 1.10 (1.02–1.19) | < 0.001 | ||||
| ≤ 9 | 18 | 1.23 (0.96–1.57) | < 0.001 | 1.15 (0.96–1.39) | < 0.001 | 1.15 (0.98–1.35) | < 0.001 | 1.17 (0.97–1.41) | < 0.001 | 1.12 (0.99–1.28) | < 0.001 | ||||
| HWE in controls | |||||||||||||||
| Yes | 27 | 1.25 (1.08–1.43) | < 0.001 | 1.05 (0.98–1.12) | < 0.001 | 1.21 (1.08–1.36) | < 0.001 | 1.10 (1.01–1.19) | < 0.001 | 1.10 (1.03–1.18) | < 0.001 | ||||
| No | 6 | 1.23 (0.62–2.44) | < 0.001 | 1.08 (0.58–2.02) | < 0.001 | 1.22 (0.87–1.71) | 0.009 | 1.13 (0.62–2.04) | < 0.001 | 1.12 (0.80–1.56) | < 0.001 | ||||
HWE, Hardy–Weinberg equilibrium; Het, heterogeneity; HCC, hepatocellular carcinoma; SCCHN, squamous cell carcinoma of head and neck; HB, hospital based; PB, population based.